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Abstract
The serotonergic hallucinogen psilocybin has characteristic eﬀects on human brain
activity and subjective experience. Previous functional magnetic resonance imaging
(fMRI) studies showed alternations of functional connectivity (FC) under the inﬂuence
of psilocybin in humans. No study, as yet, investigated psilocybin-induced changes
in brain hemodynamics and oxygenation with functional near-infrared spectroscopy
(fNIRS) optical neuroimaging. Our aim was to perform the ﬁrst fNIRS single-subject
pilot study in order to investigate the ability of fNIRS to detect changes induced by
psychedelic substances. To this end, psilocybin (17 mg) was administered orally to a
31-year old man while resting-state changes in cerebral tissue hemodynamic and oxy-
genation were measured with fNIRS bilaterally over the frontal and occipital cortex.
Measurements were performed before the intake of the substance as well as during
its eﬀective period (30 min and 60 min after intake). We observed psilocybin-induced
changes in the bilateral frontal FC, bilateral occipital FC as well as right and left fronto-
occipital FC. In addition, the pulse rate of the subject showed non-random variations
during the experiment, possibly related to psilocybin administration. This study demon-
strates that fNIRS is able to detect psilocybin-induced changes in resting-state FC. The
results of this initial single-subject pilot study are promising and warrants repetition
with a larger number of subjects and an improved/extended fNIRS setup. We anticipate
that fNIRS neuroimaging will play an important role in future studies investigating the
neuronal/physiological eﬀects of psychedelic substances in humans.
Introduction
Psilocybin (4-phosphoryloxy-N, N-dimethyltryptamine) is the active compound in
psychedelic mushrooms and its use has recently been decriminalized in two cities in
the US (Denver, Colorado, and Oakland, California) [1]. The intake of psilocybin is as-
sociatedwith various neurobiological and psychological acute and long-lasting eﬀects in
humans [2] [3] mainly mediated by changes in neurotransmitter systems. The serotonin
(5-hydroxytryptamine, 5-HT) system is most aﬀected. Psilocybin stimulates 5-HT, and
5-HT2A receptors in particular [4] [2] [3]. While the binding of psilocybin to 5-HT2A is
strongest (IC50 = 6 ± 0.5 nM), it also binds to 5-HT1A receptors (IC50 = 190 ± 40 nM) and to
a much lesser extent to 5-HT2B (IC50 = 410 ± 50) [5]. Blocking 5-HT2A receptors with the
5-HT2A antagonist ketanserin before administrating psilocybin therefore causes a dose-
dependent reduction of the neurological and psychological eﬀects normally induced by
psilocybin, highlighting the importance of the 5-HT2A agonistic eﬀect of psilocybin [6]
[7]. Besides eﬀects on the 5-HT system, psilocybin also aﬀects the dopamine (D2) system
as evidenced by a striatal dopamine release [8] and a partial reduction of the psycholog-
ical eﬀects of psilocybin after administration of the D2-antagonist haloperidol [7]. Due
to the lack of aﬃnity of psilocybin to dopamine D2 receptors (Ki = 17,000 nM) [9], this
eﬀect is most probably mediated by 5-HT receptor activation [8].
Numerous preliminary studies showed positive eﬀects of using psilocybin as an ad-
junct to treating depression [10], particularly treatment-resistant depression [11], alco-
hol dependence [12] and tobacco addiction [13] [14]. In the context of psychotherapy,
“psilocybin-assisted psychotherapy” [15] [16] has great potential for the treatment of
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a variety of psychological problems. The eﬃcacy of this treatment is mediated by per-
sonal subjective psychedelic experience [17]. In healthy humans, psilocybin increases
positive mood by decreasing amygdala reactivity [18], increases the personality domain
of openness (up to 1 year after the administration) [19], and can lead to experiences that
“were considered by volunteers to be among the most personally meaningful and spir-
itually signiﬁcant of their lives” [20].
Psilocybin-induced changes in brain metabolism as well as tissue perfusion and oxy-
genation have been seen locally and globally in the brain, accompanied with character-
istic changes in functional connectivity (FC) between brain areas (for a review see [21]
[22]).The eﬀect of psilocybin on human brain activity has been previously investigated
with functional magnetic resonance imaging (fMRI) [23] [24] [11] [25] [18] [26] [27]
[28], arterial spin labeling (ASL) magnetic resonance imaging [29], electroencephalog-
raphy (EEG) [30] [31] [32] [33] [34] [35] [36] [37], positron emission tomography (PET)
[38] [39] [8] and magnetoencephalography (MEG) [40], but not yet with optical neu-
roimaging based on functional near-infrared spectroscopy (fNIRS). fNIRS has the ad-
vantage over fMRI of having a higher temporal resolution, delivering information about
hemodynamics and cerebral tissue oxygenation independently, and not requires mo-
tionless measurements, which reduces the possibility of experimental stress.
Objective
Our objective was to investigate the potential of optical neuroimaging with fNIRS to
detect changes in a subject’s brain resting-state functional connectivity (RSFC) after
intake of psilocybin. The fNIRS technique enables non-invasive measurements of rela-
tive changes in hemodynamics and oxygenation (associated with brain activity due to
neuro-vascular coupling) by shining light into the head at diﬀerent wavelengths in the
red/near-infrared wavelength region, measuring the diﬀusively back-reﬂected light and
determining the concentration changes of the oxygenation state of hemoglobin (asso-
ciated with tissue perfusion and oxygenation) [41]. fNIRS is increasingly used in neu-
roscientiﬁc studies in humans due to its relatively low cost, portability, unique ability
to diﬀerentiate between tissue hemodynamics and oxygenation with one measurement,
and noiseless use that prevents disturbance of the subject during the experiment.
This is the ﬁrst report evaluating the application of fNIRS to investigate changes in cere-
bral hemodynamics and oxygenation induced by the intake of a psychedelic substance
in general and psilocybin in particular.
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a
Figure Legend
Figure 1. Changes in resting-state functional connectivity due to psilocybin
administration.
(A) Functional connectivity matrices for the three conditions (before and after psilocy-
bin administration (0 min, 30 min, 60 min) and 4 intervals (of a duration of 3.5 min each;
sequence: eyes closed, eyes open, eyes closed, eyes open).
(B–F) Coupling strength values derived from the FCMs for all connections possible (B),
bilateral frontal functional connectivity (BF-FC) (C), bilateral occipital functional con-
nectivity (BO-FC) (D), right fronto-occipital functional connectivity (R-FO-FC) (E) and
left fronto-occipital functional connectivity (L-FO-FC) (F).
(G) Changes in pulse rate during the experiments.
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(H) Position of the fNIRS light emitters and detectors on the subject’s head. The MRI
images correspond to a template implemented in the Brain Viewer software.
(I) Diagram of the key steps of fNIRS signal processing employed.
(J) fNIRS signal quality, as determined by the light-tissue coupling index (LTCI), for the
16 channels used in the study.
VC: visual cortex. PFC: prefrontal cortex. The asterisks indicate statistically signiﬁcant
(p < 0.05) diﬀerences to the baseline levels (phase 1).
Results & Discussion
The present experimental procedure consisted of 3 phases. Phase 1: baseline, before
psilocybin administration, phase 2: 30 min after psilocybin administration, and phase
3: 60 min after psilocybin administration (Fig. 1A–F). Changes in FC during each phase
were investigated by dividing each phase into 4 intervals (with a duration of 3.5 min
each) during which the subject was asked to close and open his eyes, respectively. We
observed changes in bilateral frontal FC (BF-FC) as well as right and left fronto-occipital
FC (R-FO-FC, L-FO-FC) with respect to phases 1–3 of the experiment. In particular, dur-
ing phase 2 the coupling strength (CS) in BF-FC, R-FO-FC, and L-FO-FC showed changes
with respect to phase 1 (baseline) (Fig. 1C, E, F). BF-FC showed a statistically signiﬁ-
cant (p = 0.0181) increase compared to baseline (phase 1) at interval 3 in phase 2 (Fig.
1C). R-FO-FC and L-FO-FC ﬁrst decreased signiﬁcantly below baseline (p = 0.0393 and
p = 0.0072, respectively) before increasing above baseline with the increase in R-FO-
FC in interval 4 being statistically signiﬁcant (p = 0.0449) (Fig. 1E). Psilocybin-induced
changes in FC thus occurred 30–45 min (phase 2) after administration in BF-FC, R-FO-
FC, and L-FO-FC. No signiﬁcant change was detected in bilateral occipital FC (BO-FC)
(Fig. 1D), but an increasing tendency when analyzing the global FC (Fig. 1B).
The ANOVA revealed no main eﬀects of condition (before drug administration, 30 min
afterward and 60 min afterwards) nor time (4-time intervals) for all FC types investi-
gated, but a signiﬁcant interaction eﬀect between time and condition for the CS values
linked to the BF-FC (F = 2.663, p = 0.017) and L-FO-FC (F = 2.479, p = 0.026). This high-
lights the relatively fast changes in RSFC dynamics induced by psilocybin.
Pulse rate (PR) signiﬁcantly dropped during the experiment (p <0.01) in phase 3 com-
pared to phase 1 (1.452 ± 0.033 Hz vs. 1.534 ± 0.046 Hz, d = 2.041) and phase 2 (1.452 ±
0.033 Hz vs. 1.530 ± 0.068 Hz, d = 1.431). During phase 2, PR increased and decreased
intermittently (Fig. 1G).
We noticed that the recorded fNIRS signals had a diﬀerent signal-to-noise ratio (SNR)
values, quantiﬁed by the light-tissue coupling index (LTCI). Only 3 of the 16 channels
(18.75 %) had a LTCI value associated with a SNR that would enable reliable detection
of small changes in cerebral hemodynamics and oxygenation. Based on this ﬁnding,
it has to be concluded that our inability to detect strong changes in FC elicited by the
psilocybin administration is more likely to be caused by an insuﬃcient SNR of the fNIRS
data instead of the absence of a change in FC. The 13 channels without optimal LTCI
could still be used in the present analysis since the signals were properly ﬁltered and the
signals contained valuable information in the low-frequency domain, which was used
in the FC analysis.
Our observation that the most pronounced changes in FC occurred in phase 2 (30–45
min after administration) suggests that this time-frame may also include the strongest
neurophysiological eﬀects. Previous studies (involving psilocybin with doses of 10 and
25 mg) concluded that “acute psychedelic eﬀects typically become detectable 30–60 min
after dosing, peak 2–3 h after dosing, and subside to negligible levels at least 6 h after
dosing” [42]. Our fNIRS FC measures thus responded most likely to the initial phase of
the psilocybin eﬀect.
Functional brain connectivity patterns during the resting-state can be separated into
the default mode network (DMN), executive control network (ECN), salience network,
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dorsal attention network (DAN), auditory network, sensorimotor network and the visual
network (VN) [43]. The observation of our study that the R-FO-FC and L-FO-FC showed
a change with respect to baseline can be interpreted as a change in the coupling of the
ECN or DAN (covering the frontal cortex) with the VN (covering the occipital cortex).
How do our results compare to PET, ASL and fMRI RSFC ﬁndings reported in previous
psilocybin studies? A direct comparison is diﬃcult since (i) we used a new technique
that has its own sensitivity and speciﬁcity with respect to changes in hemodynamics
and oxygenation associated with brain activity, and since (ii) available RSFC investiga-
tions based on fMRI applied diﬀerent experimental designs than the one used in our
study; for example, previous RSFC fMRI studies administered psilocybin intravenously
(i.v.) [23] [24] [44] [45] [46] [47], whereas oral administration was used in our case.
An i.v. administration of psilocybin causes a fast onset of psychological symptoms and
neurophysiological alternations, peaking after approx. 4 min with a steady decline in
the following 20 min (i.v. administration of 2 mg psilocybin) [48]. In the ﬁrst study
reported on psilocybin, Carhart-Harris et al. used fMRI and ASL to investigate regional
changes of cerebral blood ﬂow (CBF) and FC [23]. A decrease in the blood-oxygen-
level-dependent (BOLD) signal and in CBF was found in regions such as the medial
prefrontal cortex (mPFC), a central part of the DMN, associated with a decrease in FC
between the mPFC and the posterior cingulate cortex. A change in FO-FC as observed
in our study has not been reported in this study. Several other publications re-analyzed
the study of Carhart-Harris et al. with respect to additional enquiries. These studies
found a psilocybin-induced increased FC between the DMN and the right frontopari-
etal network, auditory network and salience network [44], changes in the complexity of
FC [46] [47], increase in BOLD signal variance in the bilateral hippocampi and anterior
cingulate cortex [49] [47], and a general increase in the coupling between some of the
resting-state networks (with a decrease in coupling in only a few) [28]. Our observation
of a change in the right and left FO-FC was also detected in the study by Roseman et al.
[28] who noticed an increase in the coupling between the VN and the DANwhich covers
parts of the region measured in the frontal cortex in the present study. Our observation
of a change in the coupling between the right and left PFC has not been reported so far,
to the best of our knowledge.
Other physiological responses to psilocybin have been reported such as an increase
in the heart rate (HR), in parallel with an increase in body temperature, respiration
rate, and blood pressure [50]. Transient increases in heart rate and blood pressure (∼15
bpm and systolic blood pressure (SBP) increases of ∼20 mm Hg) have been found as
acute eﬀects of i.v. psilocybin administration [48]. However, no signiﬁcant changes
in heart rate or blood pressure have been previously reported after the intake of 10 or
25 mg of oral administration psilocybin [42]. Our ﬁnding of an increased HR during
phase 2 (30–45 min after administration) and a decreased HR (with respect to baseline)
during phase 3 (60–75min after administration) is thus partially in agreement with these
ﬁndings. A direct comparison, however, cannot be made, since the studies investigating
HR changes after psilocybin intake did not report the exact time point of HR assessment.
It might be also the case that the HR decrease in phase 3 was caused by increases in
tiredness and relaxation of the subject.
The changes in PR suggest a possible change in vascular tone in the cerebral as well
as extracerebral tissue due to changes in the autonomic nervous system activity linked
to changes in cardiorespiratory activity. Indeed, the vasoactive properties of psilocy-
bin have been reported [51]. While 5-HT receptor-mediated vasoconstriction appears
obvious, there are indications that this mechanism is not the only one [51]. If the vas-
culature was aﬀected by psilocybin during our experiment, the fNIRS signals (as well as
BOLD signals recorded with fMRI) would have been aﬀected by this. This aspect should
be considered when interpreting the FC fNIRS data and for future fNIRS experiments
investigating the physiological eﬀects of psilocybin.
Conclusions
In our single-subject fNIRS study, we detected changes in RSFC during psilocybin ad-
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ministration with respect to BF-FC, R-FO-FC and L-FO-FC and associated changes in
PR. Our results indicate that fNIRS is able to detect psilocybin-induced changes in RSFC
thereby oﬀering a new brain imaging modality to investigate neural and physiologi-
cal eﬀects induced by psilocybin. Our single-subject study requires repetition within a
larger number of subjects and an optimized fNIRS setup (including measurement chan-
nels with short source-detector distances, and broader coverage of cortical regions).
Measurements with fNIRS have great potential to capture fast dynamical changes of
RSFC during psilocybin intake (due to its high time resolution) and are able to capture
physiological changes with only minimal disturbance of the subjects as compared to
fMRI. We expect that fNIRS will play an important role in future human studies inves-
tigating the eﬀects of psychedelics in general.
Limitations
Being a pilot study, the main limitation of our study is that data were collected from
only one subject. Nevertheless, our study provides important information on how fu-
ture fNIRS studies on the eﬀects of psychedelics on cerebral hemodynamics and oxy-
genation could be improved. Our suggestions are: (i) A good SNR (with a high LTCI
for each fNIRS channel) must be ensured for the recorded fNIRS signal. This can be
realized for example by optimizing the positioning of the light detectors and sensors on
the subject’s head. (ii) A larger number of channels is advantageous. Such high-density
FC fNIRS measurements (with up to 1200 source-detector channels) have been already
demonstrated [52] [53]. (iii) In the present study, only long source-detector channels
with a source-detector distance (SDS) of about 3 cm have been used. Having additional
channels with short SDS would enable the assessment of changes in hemodynamics
and oxygenation originating from extracerebral tissue. Such extracerebral changes can
impede the signal originating from deeper layers (cerebral) and can lead to misinterpre-
tation of the fNIRS signal [54] [41] [55]. Adding channels with a short SDS is therefore
recommended for future fNIRS studies. Methods are available to regress out extracere-
bral inﬂuences (e.g. [56] [57] [58]). (iv) Changes in respiration and autonomic nervous
system can modulate both hemodynamics in the cerebral and extracerebral compart-
ment which could also negatively inﬂuence the fNIRS measurements [54] [59] [60] [61]
[41] [55]. The removal of these systemic hemodynamic ﬂuctuations is important for
fMRI as well as fNIRS. While fMRI provides the availability of standardized methods
to remove systemic inﬂuences [62] [63], methods addressing this type of confounding
factors are still under development for fNIRS [64] [49]. As in the case of the BOLD sig-
nal [63], fNIRS signals are not a direct measure of neural activity but reﬂect a complex
combination of changes in metabolism (CMRO2), blood ﬂow and blood volume. (v) A
continuous measurement over the whole time course (e.g. 2–3 h) could be advantageous
to detect changes in RSFC induced by psychedelic substances in order to optimally cap-
ture the dynamics of FC. In the present study, phases 1, 2 and 3 were 15 min apart,
resulting in a discontinuous measurement.
Alternative Explanations
Additional Information
Methods
Subject and experimental protocol
A 31-year old male participated in the study and gave written consent. The study was
approved by the ethics committee of the Canton Zurich (KEK-ZH-Nr: 2013-0434) and
conducted in accordance with the Declaration of Helsinki. Data, in anonymous format
(according to data protection policy in the ethics agreement), are available on request.
3 fNIRS measurements were conducted in a male subject before and after (30 min and 60
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min) psilocybin administration. Each measurement lasted about 15 min. The ﬁrst mea-
surement was conducted at 9:15 am, the second one at 10:20 am, and the third one at
11:00 am. The 3 single measurements constituted 3 phases of the measurement (baseline
resting-state, 30 min, and 60 min after administration). An oral dose of 17 mg psilocy-
bin was administrated to the participant. During each measurement, the participant
was asked to rest quietly in a chair and verbal instructions were given during the mea-
surement to open or close both eyes. During each 15 min measurement, the subject had
to repeatedly close and open his eyes each for a duration of 3.5 min. Each of the 3.5 min
intervals was used separately for the FC analysis.
Functional near-infrared spectroscopy instrumentation
RSFC measurement was performed with a NIRSport instrument (NIRX Medizintech-
nik, Berlin, Germany) consisting of 8 light detectors (silicon photodiodes) and 8 light
emitters (dual-wavelength light-emitting diodes with 760 nm and 850 nm) at a sampling
rate of 7.81 Hz. The light sources and detectors were placed on the head of the subject
with help of a speciﬁc cap and were positioned over the bilateral prefrontal cortex as
well as the occipital cortex (see Fig. 1H). The exact positioning of the sources and detec-
tors was performed according to the 10–20 system. The source-detector separation was
about 3 cm. The data acquisition board was connected to a notebook computer running
LabVIEW 2011 (National Instruments, Austin, TX, USA).
Functional connectivity analysis
The recorded optical data were converted into relative (to the ﬁrst measurement time-
point) concentrations of oxyhemoglobin (Δ[O2Hb]) and deoxyhemoglobin (Δ[HHb]),
here referred to as fNIRS signals, with the use of the modiﬁed Beer-Lambert law (ab-
sorption coeﬃcients (μa) for O2Hb: μa (760 nm) = 1486, μa (850 nm) = 2526, for HHb: μa
(760 nm) = 3843, μa (850 nm) = 1798; diﬀerential pathlength factor (DPF): DPF (760 nm)
= 7.25, DPF (850 nm) = 6.38).
The fNIRS signals were band-pass ﬁltered (0.008–0.15 Hz, ﬁnite-impulse response ﬁlter,
zero-phase ﬁltering, ﬁlter order: 2000) in order to extract spontaneous ﬂuctuations of
oxygenation and hemodynamics and downsampled to a sampling rate of 1 Hz. The
frequency range 0.008–0.15 Hz was chosen according to the ﬁndings of Braun et al. [65]
reporting this frequency band as the most reliable for resting-state connectivity, and
the high ﬁlter order was chosen according to recent ﬁndings of optimal fNIRS signal
processing [66].
The quality of the recorded signals, with respect to the SNR, was ﬁrst inspected visu-
ally for each channel and secondly quantiﬁed by calculating the LTCI using Δ[O2Hb]
according to LTCI = HRP/HFNP, with HRP being the heart rate power (sum of the ab-
solute value of the ﬁltered signal in the frequency range 0.5–2 Hz) and HFNP being the
high-frequency noise power (sum of the absolute value of the signal ﬁltered with a high-
pass ﬁlter at a cutoﬀ frequency of 2 Hz). The LTCI corresponds to the magnitude of the
blood volume pulsation present in the fNIRS signals with respect to the high-frequency
noise primarily caused by improper light-tissue coupling. The LTCI thus representing
the SNR. Figure 1J depicts the LTCI values for all channels. Channel 13 had to be dis-
carded from further analysis due to a technical problem. 3 of the channels exhibited a
high LTCI value compared to the others, indicating a good SNR. For the analysis, all 15
available fNIRS channels were used despite the diﬀerences in LTCI and thus SNR values
between the channels. The rationale for doing this was our experience from previous
fNIRS studies that channels with a lower SNR still contain low-frequency ﬂuctuations
and thus information relevant for resting-state connectivity analysis.
For each of the 3 phases and 4 intervals of the experiment, a functional connectivity ma-
trix (FCM) was calculated by correlating all available channels with each other, i.e. the
FC was evaluated to 12 intervals with a duration of 3.5 min each. For the FC calculations
Δ[HHb] was used since it is less inﬂuenced by confounding (non-neuronally related)
physiological factors compared to Δ[O2Hb] and total hemoglobin Δ[tHb] [55]. The cor-
relation was determined by calculating the distance correlation (dCor) between pairs of
signals. With the use of dCor we also captured non-linear correlations and accessed
8the degree of dependence between two signals in a robust way [67] [68]. The overall
coupling strength, CS, was determined for the following regions of interest (ROIs): bilat-
eral frontal cortex (accessing BF-FC), bilateral occipital cortex (accessing BO-FC), right
fronto-occipital cortex (accessing R-FO-FC) and left fronto-occipital cortex (accessing
L-FO-FC).
Pulse rate extraction from functional near-infrared spectroscopy signals
From the channel with the highest LTCI (i.e. channel 1), the instantaneous PR (an esti-
mate of the HR) was determined by ﬁrst decomposing the signal in the time-frequency
domain with a wavelet transform and then detecting the instantaneous frequency of
the main oscillation using the method and code developed by Iatsenko et al. [69]. The
ability and validity to extract the PR from fNIRS signals has been previously reported
[70] [71] [72] [73] [74].
Statistical analysis
Data were analyzed using JASP (version 0.9.2.2) employing analysis of variance
(ANOVA) and calculating the eﬀect size (Cohen’s d). Pairwise analysis of variables
(two-sided Wilcoxon rank sum test) was done using Matlab (version 2016b). Results
were regarded as statistically signiﬁcant if p < 0.05.
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